The INSPIRE International Lung Trial with the Organ Care System Technology (OCS™)

Warnecke, G.; Weigmann, Benno; Raemdonck, Dirk Van; Massard, Gilbert; Santelmo, Nicola; Falcoz, Pierre-Emmanuel; Olland, Anne; Lesèche, Guy; Mal, Hervé; Thomas, Pascal; Rea, Federico; Marulli, Giuseppe; Knosalla, Christoph; Hetzer, Roland; Ardehali, A.; Kukreja, Jasleen; Bermúdez, C.; Moradiellos, F.J.; Varela, A.; Dhital, K.; Nagendran, Jayan; McCurry, Kenneth R.; Haverich, Axel

doi:10.1016/j.healun.2013.01.020

Cited by 15 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, acceptable lung ischemic time in Leuven is limited to 8–10 h and since a longer time was anticipated, the lungs were normothermically perfused and preserved. Based on our previous experience with the portable lung perfusion device in the Inspire trial , it was considered that normothermic EVLP would limit the cold ischemic injury and could prolong ex vivo preservation. Review of the literature revealed that 11 h 15 min of clinical EVLP in our case is the longest reported .…”

Section: Discussionmentioning

confidence: 99%

Combined Liver and Lung Transplantation With Extended Normothermic Lung Preservation in a Patient With End-Stage Emphysema Complicated by Drug-Induced Acute Liver Failure

Ceulemans¹,

Monbaliu²,

Verslype³

et al. 2014

American Journal of Transplantation

Self Cite

View full text Add to dashboard Cite

Isolated lung transplantation (LuTx) and liver transplantation are established treatments for irreversible lung and liver failure. Combined liver and lung transplantation (cLiLuTx) is a less common, but approved therapy of combined organ failure, mostly applied in patients suffering from progressive cystic fibrosis and advanced liver disease. We report a patient who was listed for LuTx due to end‐stage chronic obstructive pulmonary disease and who developed drug‐induced acute hepatic failure. The only therapeutic option was hyper‐urgent cLiLuTx. To correct the poor coagulation in order to reduce the per‐operative risk of bleeding, the liver was transplanted first. In anticipation of the longer lung preservation time, cold flushed lungs were preserved on a portable lung perfusion device for ex vivo normothermic perfusion for 11 h 15 min, transplanted sequentially off‐pump, and reperfused after a total ex vivo time of 13 h 32 min and 16 h for the first and second lung, respectively. Ten months later, the patient is doing well and no rejection occurred. Normothermic ex vivo lung perfusion may help to prolong preservation time, facilitating long‐distance transport and combined organ transplantation.

show abstract

Section: Discussionmentioning

confidence: 99%

Combined Liver and Lung Transplantation With Extended Normothermic Lung Preservation in a Patient With End-Stage Emphysema Complicated by Drug-Induced Acute Liver Failure

Ceulemans¹,

Monbaliu²,

Verslype³

et al. 2014

American Journal of Transplantation

Self Cite

View full text Add to dashboard Cite

show abstract

“…Secondary effectiveness endpoints are incidence of PGD2‐3 at 72 h post‐transplantation and patient and graft survival at day 30 post‐transplantation. Interim results were presented at the 2013 annual ISHLT meeting . The trial is expected to be completed early 2014 (Table ).…”

Section: Clinical Potential and Ongoing Trialsmentioning

confidence: 99%

Ex‐vivo lung perfusion

et al. 2014

View full text Add to dashboard Cite

Summary This review outlines the new and promising technique of ex vivo lung perfusion and its clinical potential to increase the number of transplantable lungs and to improve the early and late outcome after transplantation. The rationale, the experimental background, the technique and protocols, and available devices for ex vivo lung perfusion are discussed. The current clinical experience worldwide and ongoing clinical trials are reviewed.

show abstract

“…The 30-day survival was 100 %, one patient died at day 140 after transplant from cardiomyopathy of unknown origin. In 2013, the INSPIRE trial investigators (NCT01630434), presented their interim results after 60 lung transplants at the International Society of Heart and Lung Transplantation Society meeting in Montreal [23]; unfortunately, the published abstract does not provide information other than the number of lungs preserved using this methodology. Table 4 International clinical experience with EVLP as a method re-assess and or recondition lungs EVLP as a Method to Re-assess and or Recondition Organs from the Unused Lung Donor Pool…”

Section: Clinical Experiences With Evlpmentioning

confidence: 99%

International Clinical Experiences with Ex Vivo Lung Perfusion

Sánchez

Griffith

2014

Curr Surg Rep

View full text Add to dashboard Cite

Ex vivo lung perfusion has been proposed as a method to identify good quality organs from the suboptimal donor pool, and as a method to reduce cold ischemic times by using a transportable system. As lung transplant centers adopt this new technology, encouraging reports are being published. In addition, single center experiences are now being validated by prospective and multicenter clinical trials. In the present report, we will summarize the rationale behind the use of ex vivo lung perfusion, the current different methodologies, and the published international experiences with its use.

show abstract

The INSPIRE International Lung Trial with the Organ Care System Technology (OCS™)

Cited by 15 publications

References 0 publications

Combined Liver and Lung Transplantation With Extended Normothermic Lung Preservation in a Patient With End-Stage Emphysema Complicated by Drug-Induced Acute Liver Failure

Combined Liver and Lung Transplantation With Extended Normothermic Lung Preservation in a Patient With End-Stage Emphysema Complicated by Drug-Induced Acute Liver Failure

Ex‐vivo lung perfusion

International Clinical Experiences with Ex Vivo Lung Perfusion

Contact Info

Product

Resources

About